ADVERTISEMENT
Chemotherapy De-escalation for HER2-Positive Early Breast Cancer
3-Year Invasive Disease-Free Survival Results From the PHERGain Trial
3-Year Invasive Disease-Free Survival Results From the PHERGain Trial
Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.
Source:
Cortes J, Pérez-García JM, Ruiz Borrego M, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract LBA506
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of INSERT BRAND or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement